Pfizer (PFE) Short term Debt (2016 - 2025)
Historic Short term Debt for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $4.3 billion.
- Pfizer's Short term Debt fell 5563.46% to $4.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 billion, marking a year-over-year decrease of 5563.46%. This contributed to the annual value of $6.9 billion for FY2024, which is 3288.89% down from last year.
- Per Pfizer's latest filing, its Short term Debt stood at $4.3 billion for Q3 2025, which was down 5563.46% from $4.3 billion recorded in Q2 2025.
- Pfizer's Short term Debt's 5-year high stood at $11.9 billion during Q2 2024, with a 5-year trough of $645.0 million in Q2 2022.
- For the 5-year period, Pfizer's Short term Debt averaged around $5.2 billion, with its median value being $4.3 billion (2025).
- As far as peak fluctuations go, Pfizer's Short term Debt plummeted by 8517.92% in 2022, and later skyrocketed by 54930.23% in 2023.
- Over the past 5 years, Pfizer's Short term Debt (Quarter) stood at $2.2 billion in 2021, then soared by 31.41% to $2.9 billion in 2022, then surged by 251.44% to $10.4 billion in 2023, then crashed by 32.89% to $6.9 billion in 2024, then tumbled by 38.05% to $4.3 billion in 2025.
- Its Short term Debt was $4.3 billion in Q3 2025, compared to $4.3 billion in Q2 2025 and $4.5 billion in Q1 2025.